R-CHOP Chemotherapy for Disseminated Mycobacterium avium Complex Disease due to Anti-Interferon-Gamma Autoantibodies: A Case Report | Zendy

Shunsuke Uno | Zendy; Eisuke Uehara | Zendy; Toshiki Kimura | Zendy; Takuro Sakagami | Zendy; Ho Namkoong | Zendy; Sho Uchida | Zendy; Yoshifumi Uwamino | Zendy; Naoki Hasegawa | Zendy

Open Access

R-CHOP Chemotherapy for Disseminated Mycobacterium avium Complex Disease due to Anti-Interferon-Gamma Autoantibodies: A Case Report

Author(s) -

Shunsuke Uno,

Eisuke Uehara,

Toshiki Kimura,

Takuro Sakagami,

Ho Namkoong,

Sho Uchida,

Yoshifumi Uwamino,

Naoki Hasegawa

Publication year - 2021

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofab181

Subject(s) - medicine , rituximab , chop , vincristine , prednisolone , cyclophosphamide , mycobacterium avium complex , autoantibody , chemotherapy , lymphoma , immunology , antibody

A 77-year-old Japanese man with disseminated Mycobacterium avium complex (MAC) disease due to anti-interferon-gamma autoantibodies received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy because of non-Hodgkin lymphoma complication. The hepatobiliary nodules due to MAC resolved with R-CHOP and multidrug antimycobacterial treatment. R-CHOP could serve as an alternative adjunctive therapy for patients with anti-interferon-gamma autoantibodies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research